Anthem Biosciences Ltd
NSE:ANTHEM
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
A
|
Anthem Biosciences Ltd
NSE:ANTHEM
|
356.6B INR |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
204.8B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
152.3B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
76.8T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
35.6B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
277.4B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
37B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
30.6B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.3B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
22.6B USD |
Loading...
|
Market Distribution
| Min | -305 007.7% |
| 30th Percentile | 2.1% |
| Median | 5.8% |
| 70th Percentile | 11.6% |
| Max | 1 221 633.3% |
Other Profitability Ratios
Anthem Biosciences Ltd
Glance View
Anthem BioSciences Ltd. engages in contract research, development and manufacturing, and organization with fully integrated operations spanning across drug discovery, development and manufacturing. The company is headquartered in Bangalore, Karnataka and currently employs 2,062 full-time employees. The company went IPO on 2025-07-21. The firm helps new and established biotech’s and big pharma, develop, optimize and test proteins, monoclonal antibodies, peptides, large molecules, small molecules, toxins and much more. In addition to product research and development, it helps test drugs for safety, efficacy (in vitro and in vivo), pre-clinical animal studies in a GLP facility, clone development, antibody drug conjugates, research and development and manufacture of highly potent compounds, flow chemistry-based production and large-scale commercial product manufacture. Its product line includes human nutrition, animal health, and industrial products. Under human nutrition, it offers active pharmaceutical ingredients, dietary supplements, probiotics, and enzymes, among others.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Anthem Biosciences Ltd is 24.5%, which is below its 3-year median of 28.9%.
Over the last 2 years, Anthem Biosciences Ltd’s Net Margin has decreased from 36.4% to 24.5%. During this period, it reached a low of 24.5% on May 1, 2025 and a high of 36.4% on Mar 3, 2023.
